Drugs / OLX10010
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03569267 | May 2018 → Jun 2019 | reactive cutaneous fibrous lesion | Olix Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT04877756 | Aug 2021 → Jan 2023 | reactive cutaneous fibrous lesion | Olix Pharmaceuticals, Inc. | Completed | Met primary |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2024-04-26 | Olix Pharmaceuticals, Inc. | Results 올릭스 비대흉터치료제, 2a상에서도 안전성 이슈 全無 olixpharma.com ↗
올릭스가 수령한 임상결과보고서에서는 동 안전성 평가 항목을 모두 통과하여 OLX10010의 안전성이 입증됐다. |
| 2024-04-26 | Olix Pharmaceuticals, Inc. | Results 올릭스, 비대흉터치료제 美 2a상 최종 임상결과보고서 수령 olixpharma.com ↗ |
| 2018-05-30 | Olix Pharmaceuticals, Inc. | Regulatory CTA approval for Phase 1 in UK olixpharma.com ↗ |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-04-26 | Olix Pharmaceuticals, Inc. | 올릭스 비대흉터치료제, 2a상에서도 안전성 이슈 全無 olixpharma.com ↗ |
| 2024-04-26 | Olix Pharmaceuticals, Inc. | 올릭스, 비대흉터치료제 美 2a상 최종 임상결과보고서 수령 olixpharma.com ↗ |
| 2018-05-30 | Olix Pharmaceuticals, Inc. | CTA approval for Phase 1 in UK olixpharma.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OLX10010 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04877756 ↗ |
| Modality | Small interfering RNA (siRNA) | “an siRNA therapeutic” NCT03569267 ↗ |
| Route | Subcutaneous | “OLX10010 administered subcutaneously” NCT03569267 ↗ |